- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04067934
JUMP Inflammatory Bowel Disease Study (JUMP IBD)
The Feasibility of Jumping Based Exercise to Improve Musculoskeletal Outcomes in Children and Adolescents With Inflammatory Bowel Disease (The JUMP IBD Study)
Children and adolescents with inflammatory bowel disease are at increased risk of poor bone and muscle health through a variety of factors, including underlying disease processes, nutritional deficits, and reduced physical activity.
Inflammatory bowel disease can also delay the onset of puberty in children, and pubertal development in adolescents, resulting in sub-optimal adult bone mass, therefore increasing future risk of fractures and osteoporosis. High impact exercise may be a useful additional therapy for adolescents with IBD, as the mechanical strains produced during this type of exercise, through high force muscular contractions and ground reaction forces, can promote bone formation and gains in muscle mass. There have been no previous studies assessing the effects of high impact exercise in IBD, so it is unknown if this type of exercise is feasible in this population. The aim of this study is to assess the feasibility of a short term jumping based exercise intervention for improving muscle and bone outcomes in children and adolescents with inflammatory bowel disease.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study will incorporate a pilot/feasibility design, aiming to recruit a cohort of 15 inflammatory bowel disease patients of child and adolescent age (10 - 17.9 years). No control group will be recruited.
After potential recruits have contacted the study team to signal their interest in participation, a member of the team will contact them to discuss details of the study in more depth, and assess their suitability for participation against the inclusion/exclusion criteria. If eligible, and willing to participate, they will be asked to attend a baseline session (<28 days prior to exercise intervention) during which they will be afforded the opportunity to ask any questions they may have regarding the study.
This visit will last approximately 1.5 hours. Parent/guardian will also be encouraged to ask any questions they may have. Fully informed written consent with be obtained from the participant's parent/guardian if aged under 16 years, and written informed consent (or assent, depending on competence) will also be taken from the participant. A baseline blood sample will be collected at this session by a research nurse. Participants will complete a range of questionnaires regarding quality of life (IMPACT III, PedsQL Generic Core Scale), fatigue (PedsQL Multidimensional fatigue scale), self-efficacy for exercise. A member of the study team will measure disease activity using a clinical questionnaire (wPCDAI, PUCAI). Demographic and disease history data, and physical measurements including height, sitting height, weight, body composition (bio-electrical impedance) will also be collected. Participants will be provided a wrist-worn accelerometer to measure their habitual physical activity for the proceeding seven days, which they will be instructed to return in a provided pre-paid envelope. A kit will be given for participant to provide a stool sample, to be brought to the following study visit. The exercise intervention will consist of four weeks of three jumping based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise. Participants will be requested to attend a one hour face-to-face session at the beginning of each intervention week so a member of the study team can teach them safe and correct execution of each of the prescribed movements for that week. Participants will be provided with an exercise log diary in which they can record adherence to each session, and detail if they have experienced any pain or falls (adverse events), or if anything has prevented them from participating in the prescribed session. Should they be unable to attend any face-to-face session, the exercise diary contains details of the prescribed exercises, and how to perform them. A member of the research team will make telephone contact with research participants and their parent/guardian once per week throughout the four weeks, on any week that they do not attend a face to face exercise session. As a minimum, participants will be expected to attend their first exercise session face-to-face with a member of the research team. Participants will be requested to wear a wrist-worn accelerometer throughout the intervention period, which will be routinely downloaded at each face-to-face session.
Follow-up visits will be completed <14 days post-intervention, at which all of the measurements from the baseline visit will be conducted again (excluding height, habitual physical activity.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Glasgow, Verenigd Koninkrijk
- NHS Greater Glasgow and Clyde
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- confirmed diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis) at least 6 months prior to study involvement
- aged 10 to 17.9 years (inclusive)
- ability to provide written informed consent, or assent with accompanying parent/guardian consent
- ability to mobilise and perform exercise independently
- disease in remission, or mildly/moderately active, according to weighted Paediatric Crohn's disease activity index (wPCDAI) or Paediatric ulcerative colitis activity index (PUCAI)
- stable medication for >4 weeks prior to study, and no planned changes of medication during study period
Exclusion Criteria:
- lack of capacity to provide consent or assent
- pregnancy (females)
- recent (<12 weeks) surgery, or planned surgery during intervention period
- significant contraindication to high-impact exercise
- significant comorbidity
- use of medication known to affect bone turnover (excluding that used to treat IBD [i.e. glucocorticoids])
- BMI > +3.5 standard deviation score (SDS)
- participating in >2 hours per week structured exercise (excluding school physical education)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Jumping exercise
High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
|
Four weeks of three jumping-based exercise sessions per week.
These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adherence to exercise protocol
Tijdsspanne: 4 weeks
|
Number of exercise repetitions/sessions completed
|
4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Bone metabolism biomarker
Tijdsspanne: Baseline and 4 weeks
|
Blood levels of bone alkaline phosphatase
|
Baseline and 4 weeks
|
|
Growth hormone axis
Tijdsspanne: Baseline and 4 weeks
|
Blood levels of Growth Hormone (GH)/Insulin-like Growth Factor (IGF) axis
|
Baseline and 4 weeks
|
|
Inflammatory cytokines
Tijdsspanne: Baseline and 4 weeks
|
Tumour Necrosis Factor (TNF)-alpha levels
|
Baseline and 4 weeks
|
|
Muscle function
Tijdsspanne: Baseline and 4 weeks
|
Jumping mechanography power output
|
Baseline and 4 weeks
|
|
Disease activity
Tijdsspanne: Baseline and 4 weeks
|
Faecal calprotectin levels
|
Baseline and 4 weeks
|
|
Health-related quality of life
Tijdsspanne: Baseline, 2 weeks and 4 weeks
|
Score on IMPACT III questionnaire: the scale measures disease specific quality of life in paediatric IBD patients; TOTAL Score is measured on a scale of 0 - 100; higher scores indicate better QoL; the questionnaire has Four sub-domains: Well-being, emotional functioning, social functioning and body image; all sub-domains also measured 0 - 100 scale, with higher scores indicating better QoL in that domain
|
Baseline, 2 weeks and 4 weeks
|
|
Fatigue
Tijdsspanne: Baseline and 4 weeks
|
Score on PedsQL Multidimensional fatigue scale: the scale measures generic fatigue in children and adults; Total score is measured on scale of 0 - 100; higher score indicates less fatigue; three sub-domains - general fatigue, sleep/rest fatigue, cognitive fatigue - scored on same 0 - 100 scale; higher score = less fatigue
|
Baseline and 4 weeks
|
|
Bio-electrical impedance as measure of Body composition
Tijdsspanne: Baseline and 4 weeks
|
Bio-electrical impedance
|
Baseline and 4 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jarod Sze Choong Wong, MBBS MRCPCH DMedSc, University of Glasgow
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GN19GA217P
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Inflammatoire darmziekten
-
University of California, San DiegoChildren's Hospital of MichiganVoltooidMultisystem Inflammatory Syndrome-KinderenVerenigde Staten
-
University of ArkansasBeëindigdPediatrische patiënten met SIRS (Systemic Inflammatory Response Syndrome)Verenigde Staten
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeOnbekendSBS - Short Bowel SyndroomFrankrijk
-
GlyPharma TherapeuticsVectivBio AGVoltooidSBS - Short Bowel SyndroomDenemarken
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc., a healthcare company...VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases